The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Gilead said it plans to start phase 3 trials later this year. SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...

Its passage in 2017 represented one of the most important lobbying victories claimed by the American Council of Engineering Companies because the measure effectively cuts taxes paid by many ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A new study published has revealed that Gilead Sciences’ Lenacapavir has shown promising results as prevention method for HIV with long-lasting effects. The annual injection can be used as a pre ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

the Fullgraf Professor in the Department of Computer Science & Engineering in the McKelvey School of Engineering, wanted to use artificial intelligence and data science to help improve adolescent ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...